These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
122 related items for PubMed ID: 11949885
1. Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats. Matsuo T, Ishikawa E, Ohta M, Shibouta Y, Ishimura Y, Imura Y, Sugiyama Y. Jpn J Pharmacol; 2002 Mar; 88(3):300-6. PubMed ID: 11949885 [Abstract] [Full Text] [Related]
2. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K, Shibouta Y. Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442 [Abstract] [Full Text] [Related]
3. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, Imura Y. Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358 [Abstract] [Full Text] [Related]
4. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats. Sugimoto K, Tsuruoka S, Matsushita K, Fujimura A. J Hum Hypertens; 1999 Jan; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923 [Abstract] [Full Text] [Related]
5. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Malmqvist K, Kahan T, Dahl M. Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401 [Abstract] [Full Text] [Related]
6. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, Rosei EA. J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855 [Abstract] [Full Text] [Related]
7. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Shibouta Y, Chatani F, Ishimura Y, Sanada T, Ohta M, Inada Y, Nishikawa K. Kidney Int Suppl; 1996 Jun; 55():S115-8. PubMed ID: 8743529 [Abstract] [Full Text] [Related]
9. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H. Am J Nephrol; 2000 Dec; 20(5):373-9. PubMed ID: 11092994 [Abstract] [Full Text] [Related]
10. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan. Ogihara T, Arakawa K. J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918 [Abstract] [Full Text] [Related]
11. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators. J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233 [Abstract] [Full Text] [Related]
12. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats. Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y. Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812 [Abstract] [Full Text] [Related]
13. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. Tanser PH, Campbell LM, Carranza J, Karrash J, Toutouzas P, Watts R. Am J Hypertens; 2000 Feb; 13(2):214-8. PubMed ID: 10701823 [Abstract] [Full Text] [Related]
14. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. Franke H. J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010 [No Abstract] [Full Text] [Related]
15. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats). Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y. Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646 [Abstract] [Full Text] [Related]
16. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. Zanchetti A, Omboni S, Di Biagio C. J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009 [No Abstract] [Full Text] [Related]
17. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Obata J, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, Inagami T. Kidney Int Suppl; 1997 Dec; 63():S229-31. PubMed ID: 9407467 [Abstract] [Full Text] [Related]
18. Candesartan cilexetil: an angiotensin II-receptor blocker. See S, Stirling AL. Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259 [Abstract] [Full Text] [Related]
19. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. Inscho EW, Imig JD, Deichmann PC, Cook AK. J Am Soc Nephrol; 1999 Jan 15; 10 Suppl 11():S178-83. PubMed ID: 9892160 [Abstract] [Full Text] [Related]
20. Angiotensin II receptor antagonist improves age-related endothelial dysfunction. Kansui Y, Fujii K, Goto K, Abe I, Iida M. J Hypertens; 2002 Mar 15; 20(3):439-46. PubMed ID: 11875311 [Abstract] [Full Text] [Related] Page: [Next] [New Search]